All In Biotech

NDA 203756 · Exelixis

Cometriq

Cabozantinib S-Malate · Oral

NovelPriority reviewOrphan

Last checked: Nov 21, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Nov 29, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

45

3 Phase 3, 6 recruiting

FAERS reports

5,563

3,912 serious, 976 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 18, 2025.

COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )

Mechanism: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2016 Supplement 2 · Efficacy LabelLetter
  • Nov 29, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
2 products under this application
  • COMETRIQ · CABOZANTINIB S-MALATE EQ 80MG BASE · CAPSULE, ORAL · Prescription
  • COMETRIQ · CABOZANTINIB S-MALATE EQ 20MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cabozantinib S-Malate" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,109
  • diarrhoea1,034
  • fatigue713
  • nausea516
  • malignant neoplasm progression477
  • decreased appetite452
  • asthenia333
  • stomatitis332
  • weight decreased329
  • death317
  • vomiting301
  • palmar-plantar erythrodysaesthesia syndrome268

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20122
2013214
2014304
2015304
2016147
2017518
2018626
2019505
2020419
2021605
2022637
2023502
2024288
2025285
2026206

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cometriq (Cabozantinib S-Malate)

2024 spending

$3.3M

Beneficiaries

41

202 claims

Per beneficiary

$81,546

$244.31 per unit

View as table
YearSpending
2020$9,076,795
2021$5,847,707
2022$3,978,052
2023$3,456,787
2024$3,343,405

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Exelixis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.